Shanghai, China, 26 August 2022 — Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™”) today announced the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 (the “Reporting Period”).
In the first half of 2022, the recurrence of COVID-19 in China has brought severe challenges to the Company. MicroPort® MedBot™ worked against the clock to allocate its resources and focused on ensuring the orderly resumption of production and operation, maintained stable progress on the research and development, clinical trials and commercialization of surgical robot products.
Tackling key technologies: Innovations in product R&D
As the only global surgical robot company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, with excellent and diverse product portfolio and growing business promotion team, MicroPort® MedBot™ has made significant process in the reporting period.
As of the press release date, the three flagship products, Toumai™ Laparoscopic Surgical Robot (“Toumai™”), DFVision™ 3D Electronic Laparoscope (“DFVision™”) and Honghu Orthopedic Surgical Robot (“Honghu”) have entered the special approval procedure for innovative medical devices in China (“Green Path”), and were approved by the NMPA. In the meantime, Honghu with registered name “SkyWalker™” in the U.S. received 510(k) clearance from the FDA in July 2022. MicroPort® MedBot™ also achieved satisfactory progress in the innovation and R&D as well as the industrialization in respect of other products during the reporting period.
Toumai™ has obtained the registration certificate for launch to be used in urological surgery issued by the NMPA, becoming the first and only four-arm laparoscopic surgical robot developed by a Chinese enterprise approved for launch as of the date of this announcement. Meanwhile, Toumai™ has completed the registrational clinical trial of laparoscopic surgery operation in the field of general surgery, thoracic surgery and gynecologic surgery in April 2022, filling the gaps of the clinical application of domestic surgery robots in various fields. Toumai™ has also become the second laparoscopic surgical robot in the world, and the first in China, to fully cover the important and complex clinical applications in the fields of thoracic cavity, abdominal cavity and pelvic cavity. With the help with 5G communication technology, Toumai™ has successfully completed the longest-distance 5G ultra-remote robotic surgery in the world as of the date of this announcement, which has demonstrated China’s breakthrough and leading position in 5G ultra-remote surgery field. Looking forward, it can help promoting the flow and reasonable allocation of quality medical resources to grassroot area, and make it more feasible to carry out surgeries of high complexity and difficulty in remote and underdeveloped areas.
In April 2022, Honghu has obtained the registration certificate for launch issued by NMPA to be used for total knee replacement surgery, making it the third flagship product of MicroPort® MedBot™ approved for launch and opened a new chapter for our comprehensive presence on the circuit of orthopedic robots. Honghu was also the first and only Chinese-developed orthopedic surgical robot approved by NMPA and FDA which is equipped with a self-developed robotic arm with proprietary intellectual property rights to date.
As of 30 June 2022, MicroPort® MedBot™ have filed 689 patents application worldwide, of which 209 patents have been granted patents in China or overseas, including 159 Chinese patents and 50 overseas patents. In the reporting period, the Company was granted 49 new patents, including 19 overseas patents for inventions, completing the overseas deployment of core technologies.
Exploring sinking market, accelerations in commercial promotion
MicroPort® MedBot™ has built a complete commercialization system, including academic promotion, clinical support and patient education. Meanwhile, the Company established >100-person consultant marketing team to provide hospitals with comprehensive services, such as training, surgery support, maintenance and device adjustment, helping the Company to improve our product marketing system, enhance service capabilities and optimize brand image. During the reporting period, MicroPort® MedBot™ made monumental progress in commercialization, Toumai™ won the bidding in the medical devices procurement for the first time, and also received sales indications from over ten hospitals.
Despite the adverse impact of the epidemic, and the penetration of large medical devices to hospitals experiencing delay, MicroPort® MedBot™ still achieved further development in marketing and clinical training. During the reporting period, with its targeted and specialized marketing strategy and training system construction plan, the Company has established more than ten clinical application and training centers across the country. These have carried out a number of surgical robot clinical training and technical support activities, and has enhanced doctor communication and patient education, laying a solid foundation for further enhancing the recognition of innovative products of MicroPort® MedBot™, as well as their subsequent large-scale commercialization.
In July 2022, the 5G remote precisive minimally invasive surgery training center jointly established by the Company and Chinese 301 Hospital was formally put into operation. Medical robot technology and the large scale application of 5G communication technology have facilitated the provision of remote medical services and offsite consultation, and has promoted the flow of quality medical resources to grassroot region, which is important for enhancing medical services in local and remote communities, and has great application prospect.
Dr Chao He, Executive Director & President of MicroPort® MedBot™ stated: ”Despite the challenges including the recurrence of COVID-19 and the conflict of international relations, MicroPort® MedBot™’s over 1,200 employees uphold the idea of innovation, passion, group wisdom and tenacity, explore and proceed in adversity, made gratifying breakthrough in fields including products innovation and commercialization. Since MicroPort® MedBot™ has been listed on the Hong Kong Stock Exchange in November 2021, every step of our development has revived warm care from our investors. We will continue to work hard to promote the development of innovative products based on the five ‘golden specialties’, fulfill our commitment to meeting the frontier demand for minimally-invasive surgery, build a globalized medical robots total solution innovation platform, realize the initial vision of making surgeries easy anywhere, and live up to the support and high expectations of all sectors of society.”
About MicroPort® MedBot™
Founded in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort® MedBot™”, stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of super intelligent surgery.
More information is available at www.medbotsurgical.com.